

B7

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/06, 5/08	A1	(11) International Publication Number: WO 99/07831 (43) International Publication Date: 18 February 1999 (18.02.99)
<p>(21) International Application Number: PCT/EP98/04882</p> <p>(22) International Filing Date: 5 August 1998 (05.08.98)</p> <p>(30) Priority Data: MI97A001898 7 August 1997 (07.08.97) IT</p> <p>(71) Applicant (<i>for all designated States except US</i>): DOMPE' S.P.A. [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): LAZZARI, Lorenza [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). REBULLA, Paolo [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). SIRCHIA, Girolamo [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
(54) Title: METHOD FOR THE EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS		
<p>(57) Abstract</p> <p>The present invention provides a method for the ex-vivo expansion of hematopoietic stem cells and a culture medium for stem cells.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR THE EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS

A large number of onco-hematologic diseases can often be treated only with bone-marrow transplantation. It is rather difficult to find a donor with identical HLA within the patient's family and thus, hematopoietic stem cell transplantation from non-related donors represents a novel therapy for those patients who need bone-marrow transplantation but do not have donor-siblings with identical HLA.

Even though the number of bone-marrow donors has increased in donors' registries, only 20-30% candidates find compatible donors, whereas ethnic minorities are poorly represented (Sonnenberg F. et al., Blood 74:2569-79, 1989).

A severe graft versus host disease (GVHD) is associated with almost 40% transplants of bone marrow obtained from a related donor and with 60-80% transplants based on non-related donors (Hows J et al., Blood; 68:1322-4, 1986).

Cord blood hematopoietic stem cells can reconstitute the human hematopoietic system and thus they represent an alternative to bone marrow stem cells. The following advantages are associated with stem cells available from placental blood (stored in cord blood banks as cryopreserved cell collections), in comparison with bone marrows available from donor registries, :

1. A good amount of placental blood can be easily obtained, without any risk either for the mother or for the newborn,

CONFIRMATION COPY

2

2. Infective agents such as cytomegalovirus (CMV) are less frequent in newborns than in adults;
3. Placental blood can be cryopreserved for many years and it is available in short time;
- 5 4. a higher possibility to find a donor also for ethnic minorities;
5. less stringent requirements of HLA match (histocompatibility);
6. a less frequent graft versus host disease (GVHD)
- 10 after transplantation with placental blood (Broxmeyer HE et al., Int. J. Cell. Cloning 8: 76-91, 1990; Broxmeyer HE et al., Proc. Natl. Acad. Sci. USA 86:3828-32, 1989).

15 So far, the use of cord blood in adult patients has encountered some problems due to the content of stem cells in a cord blood unit, which is frequently not sufficient for transplantation in adults (Kurtzberg J. et al., N. Eng. J. Med. 335:157-166, 1996; Wagner JE et al., Lancet 346:214-219, 1995; Locatelli F. et al.,

20 Bone Marrow Transplant 18:1095-1101, 1996).

The high doses of chemotherapy, followed by transplantation of stem cells, provoke immunodepression in the patient who thus needs long periods of time for restoring the platelet and erythrocyte activities.

25 Furthermore, the patient needs many transfusions of several units of platelet and erythrocyte blood components, thus increasing the costs of bone marrow transplantation. The ex-vivo expansion of hematopoietic cells may play an important role in the solution of the

30 problems associated with transplantation and its costs. Clinical trials have shown that expanded cells do not

induce toxicity but, on the contrary, they offer several advantages (McAdams TA et al., Trends Biotechnol. 14:388-96, 1996). The expansion of stem cells from placental blood might improve the therapeutic approach to bone-marrow transplantation for the following reasons:

1. The ex-vivo expansion of hematopoietic precursors maintaining a non-committed population, allows
 - a) the transplantation of adult patients (Kurtzberg J et al.. N Engl J Med 335:157-166, 1996; Wagner JE et al.. Lancet 346:214-219, 1995; Locatelli F et al.. Bone Marrow Transplant 17:31-37, 1996; Locatelli F et al.. Bone Marrow Transplant 18:1095-1101, 1996)
 - b) the preparation of aliquots which can be frozen in case of relapse of the same patient (Lu L. et al.. In vivo 10:229-32, 1996)
 - c) protocols of gene therapy.
2. The ex-vivo expansion of hematopoietic precursors towards a committed population (megakaryocytes and erythroblasts) may provide a cell pool which can be frozen and transplanted into the same patient during the succeeding phases of the disease. (Lu L. et al.. In vivo 10:229-32, 1996). This procedure is in order to shorten the time to hematological reconstitution (Emerson SG. Blood 87: 3082-8, 1996).

The ex-vivo expansion is an interesting approach for maintaining hematopoietic stem cells both qualitatively and quantitatively. The cell maturation obtained through the expansion represents a crucial

point for the achievement of a suitable clinical application of the product. Actually, the expansion effectiveness and the maturation of the expanded cells can be influenced by many factors among which the static or bioreactor culture, the growth factors and the incubation period are the most critical ones (Haylock DN. et al., Blood 80:1405-12, 1992; Brugger W. et al., Blood 81:2579-84, 1993; Sato N. et al.. Blood 82:3600-9, 1993). Proliferation and maturation of hematopoietic cells are strictly regulated by factors that positively modulate primitive stem cell proliferation and multilineage or unilineage differentiation. A number of cytokines have been utilized in an attempt to promote human hematopoietic stem cell self-renewal. Although a variety of culture conditions have been defined which promote expansion of committed progenitor cells, conditions do not presently exist that permit long-term expansion of stem cells (Zijlmans JMJ et al.. Proc Natl Acad Sci USA 92:8901-5, 1995; Zijlmans JMJ et al.. Proc Natl Acad Sci USA 95:725-9, 1998; Bradford GB et al.. Exp Hematol 25:445-53, 1997; Rebel VI et al.. Blood 83: 128-36, 1994).

In fact several authors have obtained committed populations: Haylock et al.. achieved a 66-fold expansion using 6 growth factors (IL-1, IL-3, IL-6, G-CSF, SCF) and a 14-day liquid culture. Brugger et al.. obtained a 190-fold expansion with 6 factors (IL-3, IL-1, IL-6, SCF, EPO, interferon-g) in 12-14 days.

So far, no scientific investigation has furnished either the final evidence of the CD34+ stem-cell self renewal ability or a procedure through which such non-

5

committed population could be maintained. The loss of population with CD34+ immunophenotype in favour of subpopulations with CD34+/33+ and CD34+/38+ phenotype, i.e. the continuous decrease of precursors, unambiguously shows the loss of proliferative ability of the expanded precursors. Up to now, this has limited the use of expanded-cell suspensions for transplantation, in all those cases in which hematopoiesis was not supported by sources of non-purified and non-expanded stem cells.

So far, IL-3 and SCF are the most used cytokines for obtaining a precursor expansion, even if the addition of these growth factors has a negative effect, because they induce maturation of primitive stem cells (e.g. towards the neutrophil subpopulation) at the expense of self-renewal.

Two cytokines named Flt-3 and TPO have recently been found and more recently they have been deeply investigated in combination with other growth factors (Koller MR et al..., J. Hematother. 5:449-59, 1996; Kaushansky K. et al..., Nature, 369:519-20, 1995). It has been reported that c-mpl is expressed exclusively on hematopoietic tissue, particularly on CD34+ hematopoietic stem cells, megakaryocytes and platelets. Even if the role of TPO and Flt-3 is becoming increasingly evident on the normal haematopoiesis (Kaushansky K et al... Blood 86:419-31, 1995). These cytokines have been found not to have a high activity when used alone, but when combined with other cytokines, their real effect cannot be appreciated due to the presence of more potent growth factors such as IL-3 and SCF.

The CD34+38- immunophenotype defines a primitive subpopulation of progenitor cells and the maintenance of these cells continues to be a subject of ongoing study (randal TD et al.. Blood 87:4057, 1996).

5 Now, a method has been found for the ex-vivo expansion of stem cells which allows to maintain a part of the cell population in form of CD34+ non-committed cells having self-renewal properties. This method allows to maintain the expansion in constant proliferative
10 growth up to 15 weeks or more, thus obtaining the desired qualitative (CD34+/38- phenotype) and quantitative (cell number) expansion.

 The method according to the invention comprises culturing stem cells in a culture medium containing a
15 mixture of cytokines/growth factors consisting of thrombopoietin (TPO), interleukin 6, interleukin 11 (IL-6 and IL-11) and flt-3 ligand (FL).

 These components are commercially available or they can be prepared through recombinant-DNA techniques, and
20 they are added to the culture medium at a final concentration of 1 to 100 ng/ml. Preferably, each of these components is added to the culture medium at a final concentration of 10 ng/ml. The culture medium, which is a further object of the invention, contains
25 also other conventional components such as fetal bovine serum or albumin. The culture of stem cells, which can be obtained, for example, from cord blood or from other sources (e.g. bone-marrow or peripheral blood), is carried out under humidified atmosphere containing 5%
30 CO₂ for periods of time ranging from few days (for example 10 days) to several weeks (20 or more). The

7

expansion obtained by the method of the invention is clearly higher than that so far obtainable with different cytokine cocktails. In fact recently a combination of cytokines including FL+IL-6+IL-11 has been tested in a paper of Ohmizono et al.. (Leukemia 11: 524-30, 1997), but the efficiency of the expansion has been lower and for up to 21 days.

Description of figures:

Figure 1 shows the cellular expansion obtained using the method and the medium of the invention, therefore after culture of purified CD34+ cells in the presence of serum-free medium and FL+TPO+IL-6+IL-11. The Cd34+ cells were purified through separation columns and cultured for 15 weeks in serum-free medium and FL+TPO+IL-6+IL-11. Every week the cultures were demipopulated and cytokines and fresh medium were added. From the data reported in figure 1, a 10^7 -fold expansion of the number of nucleated cells is observed and it is clear that an expansion higher than 10^6 can be obtained just after 15-weeks culture.

Figure 2 shows the median of the expansion of CD34+/38- cells obtained after culture in the serum free medium containing FL+TPO+IL-6+IL-11. The cells were stained after expansion and counted by flow cytometric analysis using a FACScan analyzer. This figure shows that the number of CD34+/CD38- non-committed cells is 100.000 times higher than the initial number.

Figure 3 shows the median of expansion of CFU-GM colonies obtained in presence of serum-free medium containing FL+TPO+IL-6+IL-11. The cells were seeded in methylcellulose after expansion. This figure shows that

8

the number of CFU-GM colonies is 100.000 times higher than the initial number.

The following examples illustrate the invention in more detail.

5 EXAMPLE 1

CD34+ cell purification

 Cord Blood samples were collected after cesarean section or vaginal delivery. Cord blood was collected by venipuncturing the main vessel at the free end of the
10 cord using a Maco Pharma bag with 29 ml citrate-phosphate-dextrose (CPD) as anticoagulant. The placenta was washed out to collect the blood that remains in vessels. Mononuclear cells were isolated by Ficoll gradient (1.077 g/ml; Lympholite-H, Cedarlane
15 Laboratories, Ontario, Canada) and CD34+ cells were purified through separation columns (CellPro Inc, Bothell, Wash., USA or MiniMACS, Miltenyi, Germany).

EXAMPLE 2

 An aliquot of the CD34+ target cell fraction was
20 analyzed to determine purity by flow cytometry. The final recovery of CD34+ cells ranged from 70% to 98% of the initial CD34+ population and the analysis of the enriched cell fraction, performed with an anti-CD34+ monoclonal antibody (Becton Dickinson, Mountain View,
25 California, USA) revealed a purity of 85% to 98% CD34+ cells. The trypan-blue dye exclusion test showed a viability of 96%-99%. The CD34+ cells were seeded for the clonogenic assay.

Liquid cultures of CD34+ cells

30 CD34+ cells were plated at $3-5 \times 10^4$ /ml, in Tissue Culture Flasks. A serum-free medium containing different

concentrations of growth factors as indicated was used.

TPO, FL, IL-6 and IL-11 (PeproTech EC Ltd, London, England) were added to stroma-free liquid cultures of purified CD34+ CB cells. Cells were incubated for more than 15 weeks at 37°C in fully humidified atmosphere in 5% CO₂ air.

Clonogenic assay

Colony-forming units (CFU) were evaluated in 35 mm dishes by plating 2.5×10^3 nucleated cells in 1 ml medium containing 0.9% methylcellulose, 30% FBS, 1% BSA, 10^{-4} M 2-mercaptoethanol, 3 U/ml erythropoietin, 50 ng/ml SCF, 10 ng/ml GM-CSF, 10 ng/ml IL-3 (StemCell Technologies, Vancouver, Canada). After 14 days of culture at 37°C in a 5% CO₂ fully humidified atmosphere, cultures larger than 50 cells were scored by microscopy as colony forming cells (CFC), i.e. the sum of CFU-GM (containing granulocytes and macrophages), Burst Forming Unit-Erythroid (BFU-E, containing erythroid cells), and CFU-GEMM (containing myeloid cells, erythroid cells and megakaryocytes).

Flow Cytometry

CD34+ cultured cells were stained with one or more of the following monoclonal antibodies: anti-CD34, -CD61 (gp111a), -CD38. For flow cytometry analysis 5×10^5 cells were incubated with monoclonal antibodies for 30 minutes at 4°C and washed twice in PBS. Cells were analyzed by flow cytometry using a FACScan analyzer (Becton Dickinson) equipped with a filter set for FITC-PE dual-color fluorescence.

The percent of stained cells was determined as compared to PE- and FITC-conjugated mouse IgG1 isotypic

10

control (Becton Dickinson). Cell viability was evaluated by staining cells with 7-AAD, and viable cells were gated.

In vitro assay in NOD/SCID mice

5 The use of the ex vivo expanded cells in NOD/SCID mice is up to now an experiment to demonstrate the capacity of these expanded cells to reconstitute the bone marrow with a complete engraftment. Moreover these experiments add a new step towards the implementation of
10 clinical expansion protocols.

 The NOD/SCID mice were sublethally irradiated immediately before intravenous tail-vein injection containing an appropriate number of expanded cells. The duration of this assay was 8 weeks. Flow cytometric
15 analysis was performed on peripheral blood and bone marrow after death of mice. The presence of cells positive for human CD34+, CD19+, CD42a+ antigens was relevant after transplantation (until to 15-19%, 14-16%, 13-15% of the total cells respectively). All colonies,
20 obtained after culturing bone marrow cells (clonogenic assay), were plucked from plates and were analyzed by a human-specific PCR (Polymerase Chain Reaction): the PCR signals were positive for the human Cart-1 gene. Controls consisted of PCRs for human Cart-1 from human
25 peripheral blood leukocytes (positive) and normal mouse bone marrow cells (negative). The signals were of human origin.

 This assay has indicated the capacity of these expanded cells to home the mice bone marrows.

30

CLAIMS

1. A method for the ex vivo expansion of hematopoietic stem cells which comprises culturing said stem cells in
5 a culture medium containing a mixture of cytokines/growth factors consisting of thrombopoietin, interleukin 6, interleukin 11 and Flt-3 ligand.
2. A method according to claim 1, characterized in that the hematopoietic stem cells are obtained from cord
10 blood or other suitable sources.
3. A method according to claim 1 or 2, characterized in that the culture is maintained for a time ranging from 10 days to 15 weeks.
4. A method according to any one of the above claims,
15 in which the culture medium contains interleukin 6, interleukin 11, thrombopoietin and Flt-3 ligand, each at a concentration ranging from 1 to 100 ng/ml.
5. A method according to claim 4, in which the concentration of interleukin 6, interleukin 11,
20 thrombopoietin and Flt-3 ligand in the culture medium is 10 ng/ml.
6. A method according to claim 1 wherein the cells are 1000000-fold expanded.
7. A culture medium for hematopoietic stem cells
25 containing a mixture of cytokines/growth factors consisting of thrombopoietin, interleukin 6, interleukin 11 and Flt-3 ligand.
8. A culture of hematopoietic stem cells obtainable by the method of claims 1-6.
- 30 9. A culture according to claim 8 in which the number of CD34+/CD38- non-committed cells is 100.000


WO 99/07831

PCT/EP98/04882

12
times higher than the initial number.

SHEET 1/3


FIG.1



SUBSTITUTE SHEET (RULE 26)


SHEET 2/3

FIG. 2



SHEET 3/3

FIG. 3



SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/04882

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N5/06 C12N5/08		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OHMIZONO Y. ET AL: "Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand" LEUKEMIA, vol. 11, no. 4, April 1997, pages 524-530, XP002053902 *whole article, especially table 2*	1-9
X	WO 97 16535 A (SANDOZ LTD ;SYSTEMIX INC (US); SANDOZ AG (DE); SANDOZ AG (AT)) 9 May 1997 see the whole document	8,9
A	EP 0 627 487 A (IMMUNEX CORP) 7 December 1994 see the whole document	1-9
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 17 November 1998		Date of mailing of the international search report 23/11/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Fernandez y Branas, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/04882

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9716535 A	09-05-1997	AU 7495396 A EP 0858503 A	22-05-1997 19-08-1998
EP 0627487 A	07-12-1994	US 5554512 A AU 683472 B AU 6987794 A BR 9407073 A CA 2162397 A CN 1125479 A CZ 9503079 A FI 955646 A HU 74831 A JP 8511251 T NO 954735 A NZ 267541 A PL 311756 A WO 9428391 A ZA 9403490 A AU 2098295 A CN 1142247 A EP 0749472 A FI 963373 A NO 963630 A NZ 282999 A WO 9524469 A	10-09-1996 13-11-1997 20-12-1994 27-08-1996 08-12-1994 26-06-1996 16-10-1996 23-01-1996 28-02-1997 26-11-1996 23-01-1996 24-06-1997 18-03-1996 08-12-1994 23-01-1995 25-09-1995 05-02-1997 27-12-1996 29-08-1996 07-11-1996 19-12-1997 14-09-1995

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/06, 5/08	A1	(11) International Publication Number: WO 99/07831 (43) International Publication Date: 18 February 1999 (18.02.99)
(21) International Application Number: PCT/EP98/04882 (22) International Filing Date: 5 August 1998 (05.08.98) (30) Priority Data: MI97A001898 7 August 1997 (07.08.97) IT (71) Applicant (for all designated States except US): DOMPE' S.P.A. [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): LAZZARI, Lorenza [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). REBULLA, Paolo [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). SIRCHIA, Girolamo [IT/IT]; Via Campo di Pile, I-67100 L'Aquila (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD FOR THE EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS		
(57) Abstract The present invention provides a method for the ex-vivo expansion of hematopoietic stem cells and a culture medium for stem cells.		

THIS PAGE BLANK (USPTO)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

THIS PAGE BLANK (USPTO)

METHOD FOR THE EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELLS

A large number of onco-hematologic diseases can often be treated only with bone-marrow transplantation. It is rather difficult to find a donor with identical HLA within the patient's family and thus, hematopoietic stem cell transplantation from non-related donors represents a novel therapy for those patients who need bone-marrow transplantation but do not have donor-siblings with identical HLA.

Even though the number of bone-marrow donors has increased in donors' registries, only 20-30% candidates find compatible donors, whereas ethnic minorities are poorly represented (Sonnenberg F. et al., Blood 74:2569-79, 1989).

A severe graft versus host disease (GVHD) is associated with almost 40% transplants of bone marrow obtained from a related donor and with 60-80% transplants based on non-related donors (Hows J et al., Blood; 68:1322-4, 1986).

Cord blood hematopoietic stem cells can reconstitute the human hematopoietic system and thus they represent an alternative to bone marrow stem cells. The following advantages are associated with stem cells available from placental blood (stored in cord blood banks as cryopreserved cell collections), in comparison with bone marrows available from donor registries,:

1. A good amount of placental blood can be easily obtained, without any risk either for the mother or for the newborn,

CONFIRMATION COPY

THIS PAGE BLANK (USPTO)